Characterization of CD3+CD4-CD8- (double negative) T cells reconstitution in patients following hematopoietic stem-cell transplantation
- PMID: 21911061
- DOI: 10.1016/j.trim.2011.08.004
Characterization of CD3+CD4-CD8- (double negative) T cells reconstitution in patients following hematopoietic stem-cell transplantation
Abstract
Background: CD3+CD4-CD8-double negative (DN) T cells, as a distinct subset of regulatory T cells (Tregs), played a pivotal role in patients following hematopoietic stem-cell transplantation.
Methods: This study examines the behavior of CD3+CD4-CD8- double negative (DN) T cells in 73 patients at days 30, 60, 90 and 180 after allo-HSCT.
Results: There was no significant difference in neutrophil and platelet engraftment between the higher and lower absolute counts of 30days DN Tregs (p=0.674, 0.863, respectively). The reconstitution of DN Tregs was significantly slower than that of CD8+, CD4+, and CD3+CD8+CD28- T cells (p<0.001), but significantly faster than that of CD19+ and CD4+CD25+ T cells (p<0.001, p=0.032, respectively). Importantly, in the HLA mismatched group, DN Tregs reconstitution had significant effect on aGVHD (p=0.027) and there was significant correlation between aGVHD and DN Tregs reconstitution (p=0.035). DN Tregs reconstitution was significantly faster in the patients who were devoid of aGVHD than that of patients who developed aGVHD. Furthermore, we compared the absolute value of DN Tregs at 30days, 60days, 90days and 180days after allo-HSCT with grade aGVHD and found an inverse linear relationship in the HLA mismatched group (n=37, P<0.001, r=-0.573).
Conclusions: The successful expansion of DN Tregs at 60days after allo-HCST may help avoid severe manifestations of aGVHD in the HLA mismatched group, suggesting that DN Tregs have potential protection effect against aGVHD.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation.Biol Blood Marrow Transplant. 2012 Jun;18(6):887-93. doi: 10.1016/j.bbmt.2011.10.039. Epub 2011 Nov 4. Biol Blood Marrow Transplant. 2012. PMID: 22062803
-
Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation.Biol Blood Marrow Transplant. 2011 Apr;17(4):550-7. doi: 10.1016/j.bbmt.2010.04.011. Epub 2010 May 10. Biol Blood Marrow Transplant. 2011. PMID: 20457268
-
[Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].Nan Fang Yi Ke Da Xue Xue Bao. 2008 Apr;28(4):537-41. Nan Fang Yi Ke Da Xue Xue Bao. 2008. PMID: 18495584 Chinese.
-
Newly Found Peacekeeper: Potential of CD8+ Tregs for Graft-Versus-Host Disease.Front Immunol. 2021 Nov 24;12:764786. doi: 10.3389/fimmu.2021.764786. eCollection 2021. Front Immunol. 2021. PMID: 34899714 Free PMC article. Review.
-
Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions.J Mol Cell Biol. 2012 Feb;4(1):48-58. doi: 10.1093/jmcb/mjr043. J Mol Cell Biol. 2012. PMID: 22294241 Free PMC article. Review.
Cited by
-
Double Negative T Regulatory Cells: An Emerging Paradigm Shift in Reproductive Immune Tolerance?Front Immunol. 2022 Jul 1;13:886645. doi: 10.3389/fimmu.2022.886645. eCollection 2022. Front Immunol. 2022. PMID: 35844500 Free PMC article. Review.
-
Application of double-negative T cells in haematological malignancies: recent progress and future directions.Biomark Res. 2022 Mar 14;10(1):11. doi: 10.1186/s40364-022-00360-w. Biomark Res. 2022. PMID: 35287737 Free PMC article. Review.
-
Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer.Front Immunol. 2013 Jan 24;4:6. doi: 10.3389/fimmu.2013.00006. eCollection 2013. Front Immunol. 2013. PMID: 23355840 Free PMC article.
-
B Lymphocyte Chemoattractant (CXCL13) Is an Indicator of Acute Gastrointestinal GVHD in Murine Model.Inflammation. 2017 Oct;40(5):1678-1687. doi: 10.1007/s10753-017-0609-2. Inflammation. 2017. PMID: 28688097
-
Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.Front Immunol. 2021 May 25;12:637469. doi: 10.3389/fimmu.2021.637469. eCollection 2021. Front Immunol. 2021. PMID: 34113339 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials